{
    "clinical_study": {
        "@rank": "38678", 
        "arm_group": {
            "arm_group_label": "gp96 group", 
            "arm_group_type": "Experimental", 
            "description": "autologous gp96 vaccination + basal treatment"
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: heat shock protein gp96-peptide complex made from a person's tumor cells may help\n      the body build an effective immune response to kill tumor cells.\n\n      PURPOSE: This trial is studying the safety and effectiveness of autologous gp96 treatment of\n      glioblastoma and to see how well it works in treating patients with newly diagnosed\n      supratentoria glioma."
        }, 
        "brief_title": "Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioma", 
        "condition_browse": {
            "mesh_term": [
                "Glioblastoma", 
                "Glioma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Able to read and understand the informed consent document; must sign the informed\n             consent.\n\n          2. Aged 18 to 75 years old , sex is not limited\n\n          3. Newly Diagnosed supratentoria glioma, Must have undergone a at least a 80% resection\n\n          4. Availability of at least 1 g tumor sample.\n\n          5. Karnofsky functional status rating > or equal to 70.\n\n          6. Adequate bone marrow function including the absence of lymphopenia (ANC > 1,500/ mm3;\n             Hemoglobin > 10g/dL ; platelet count >100,000/mm3), adequate liver function (serum\n             glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], alanine amino\n             transferase [ALT] <2.5 times institutional upper limit of normals [IULNs] ), and\n             adequate renal function (BUN and creatinine <1.5 times IULNs)\n\n          7. Agree to Surgical indications of Heart & lung and without the coagulation system\n             disease\n\n          8. Negative pregnancy test for female patients of childbearing potential\n\n          9. Agree to use contraception or abstain from sexual activity from the time of consent\n             through 3 month after the end of study drug administration\n\n        Exclusion Criteria:\n\n          1. Inability to comply with study-related procedures\n\n          2. patient not suitable for Neurosurgery.\n\n          3. Unavailability of at least 6 doses of vaccine\n\n          4. Progression prior to vaccination as determined by the Principal Investigator\n\n          5. Patient with allergic constitution\n\n          6. Unstable or severe intercurrent medical conditions\n\n          7. Current diagnosis of Human Immunodeficiency Virus and Patients with active\n             uncontrolled infection.\n\n          8. patients with any systemic disease needed to be treated with immunosuppressant or\n             Corticosteroids.\n\n          9. any other clinical trials within 30 days pre-vaccination.\n\n         10. Female patients who are pregnant or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02122822", 
            "org_study_id": "CS-TT-G-01"
        }, 
        "intervention": {
            "arm_group_label": "gp96 group", 
            "description": "vaccination of autologous gp96 derived from tumor tissue + basal treatment", 
            "intervention_name": "gp96", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "supratentoria glioma", 
        "lastchanged_date": "May 3, 2014", 
        "location": {
            "contact": {
                "email": "zhixian_g@hotmail.com", 
                "last_name": "Zhixian Gao, Doctor", 
                "phone": "086-13810876745"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Beijing Tiantan Hospital Affiliated to Capital Medical University"
            }, 
            "investigator": [
                {
                    "last_name": "Nan Ji, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Zhixian Gao, Doctor", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96", 
        "overall_contact": {
            "email": "zhixian_g@hotmail.com", 
            "last_name": "Zhixian Gao, Doctor", 
            "phone": "086-13810876745"
        }, 
        "overall_official": {
            "affiliation": "Beijing Tiantan Hospital", 
            "last_name": "Zhixian Gao, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: National Health and Family Planning Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "blood count within 3 days before first vaccination", 
                "measure": "blood count", 
                "safety_issue": "Yes", 
                "time_frame": "baseline"
            }, 
            {
                "description": "blood count within 3 days after the second injection", 
                "measure": "blood count", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the second injection"
            }, 
            {
                "description": "blood count within 3 days after the 6th injection", 
                "measure": "blood count", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the 6th injection"
            }, 
            {
                "description": "blood chemistries test within 3 days before first vaccination", 
                "measure": "blood chemistries", 
                "safety_issue": "Yes", 
                "time_frame": "baseline"
            }, 
            {
                "description": "blood chemistries test within 3 days after the second injection", 
                "measure": "blood chemistries", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the second injection"
            }, 
            {
                "description": "blood chemistries test within 3 days after the 6th injection", 
                "measure": "blood chemistries", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the 6th injection"
            }, 
            {
                "description": "electrocardiogram test within 3 days before first vaccination", 
                "measure": "electrocardiogram", 
                "safety_issue": "Yes", 
                "time_frame": "baseline"
            }, 
            {
                "description": "electrocardiogram test within 3 days after the second injection", 
                "measure": "electrocardiogram", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the second injection"
            }, 
            {
                "description": "electrocardiogram test within 3 days after the 6th injection", 
                "measure": "electrocardiogram", 
                "safety_issue": "Yes", 
                "time_frame": "within 3 days after the 6th injection"
            }, 
            {
                "description": "progression-free survival rate of six month", 
                "measure": "progression-free survival rate of six month", 
                "safety_issue": "No", 
                "time_frame": "six month after surgery"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02122822"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "tumor control rate at 6th month after surgery", 
                "measure": "tumor control rate", 
                "safety_issue": "No", 
                "time_frame": "six month after surgery"
            }, 
            {
                "measure": "progress free survive", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "overall survive", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "tumor antigen specific T cells was determined by IFN-\u03b3 Enzyme-linked immunosorbent spot using the autologous tumor cell lysis as the antigen.", 
                "measure": "changes in antigen specific T cells", 
                "safety_issue": "No", 
                "time_frame": "baseline and within 3 days before the 6th injection"
            }
        ], 
        "source": "Cure&Sure Biotech Co., LTD", 
        "sponsors": {
            "collaborator": {
                "agency": "Beijing Tiantan Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Cure&Sure Biotech Co., LTD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}